Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 11/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | SRR | Q9GZT4 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 10/20 | 0.45 |
| ▸ | PSAT1 | Q9Y617 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144997 | 1.00 | SLC7A5 (0.56) | SLC7A5ESR1ESR2PPARAACE | |
| SCHEMBL1486323 | 0.86 | SRR (0.62) | SLC7A5PPARAACESRRPPARG | |
| SCHEMBL2626716 | 0.86 | SRR (0.62) | SLC7A5PPARAACESRRPPARG | |
| SCHEMBL1486321 | 0.86 | SRR (0.62) | SLC7A5PPARAACESRRPPARG | |
| SCHEMBL2501991 | 0.83 | PPARG (0.65) | PPARAACESRRPPARGPSAT1 | |
| SCHEMBL2501988 | 0.83 | PPARG (0.65) | PPARAACESRRPPARGPSAT1 | |
| SCHEMBL27886769 | 0.83 | MMP12 (0.47) | SLC7A5ESR1ESR2PPARAACE | |
| SCHEMBL4451311 | 0.82 | PPARA (0.56) | SLC7A5ESR1ESR2PPARASRR | |
| SCHEMBL4941128 | 0.82 | PPARA (0.56) | SLC7A5ESR1ESR2PPARASRR | |
| SCHEMBL3466702 | 0.82 | PPARA (0.56) | SLC7A5ESR1ESR2PPARASRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124656-A1 | Heterocyclic Oxime Compounds a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124656-A1 | Heterocyclic Oxime Compounds a Process for Their Preparation and Pharmaceutical Compositions Containing Them | GPR119, HBB, CYP3A7 | SLC7A5 3162/4885ESR1 3058/4885ESR2 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.